A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs E 6742 (Primary)
  • Indications Cancer; Neurological disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Eisai Inc
  • Most Recent Events

    • 07 Nov 2017 Planned number of patients changed from 48 to 56.
    • 07 Nov 2017 Planned End Date changed from 1 Aug 2017 to 21 Nov 2017.
    • 07 Nov 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top